Navigation Links
MCC Names ACRO Leaders to Board of Directors
Date:7/30/2008

MCC Board Expanded to Include Two ACRO Representatives

WASHINGTON, July 30 /PRNewswire-USNewswire/ -- The Association of Clinical Research Organizations (ACRO) and the Metrics Champion Consortium (MCC) are pleased to announce the appointment of two representatives from ACRO to the MCC Board of Directors. In an agreement reached earlier this month between the two groups, the MCC, a multidisciplinary organization whose mission is to develop biopharmaceutical performance standards, has expanded its Board of Directors to include two positions representing ACRO, the global association of leading clinical research organizations (CROs).

Paul Colvin, R.Ph., Senior Vice President for Clinical Development, North America, with PPD, and Sean Larkin, Senior Executive Vice President, the Americas, for Late Stage Development with PharmaNet Development Group, have been appointed by the MCC Board of Directors to join the MCC leadership on behalf of ACRO.

Mr. Colvin oversees PPD's North American Phase II-IV operational unit, providing strategic leadership to ensure delivery of international and global clinical research programs and coordination of operational processes. At PharmaNet Development Group, Mr. Larkin is responsible for the North American Regional Monitoring Network, clinical operations in Latin America and Canada, and Phase IV development services. Mr. Colvin and Mr. Larkin will assume their MCC Board seats in August 2008.

"We value the knowledge and perspective ACRO's representatives will bring to MCC's Board of Directors," said Guy Mascaro, MCC President. "ACRO's support for our organization is an important step in building a collaborative environment where sponsors and CROs can work together to improve clinical trial performance."

"The association is pleased to be represented by two outstanding industry leaders such as Paul Colvin and Sean Larkin on the MCC Board of Directors," added ACRO Executive Director Doug Peddicord, Ph.D. "ACRO looks forward to including the CRO industry's expertise on the conduct of clinical trials in MCC's initiatives and to adding the association's voice to the leadership of this valuable cross-industry organization."

ACRO's representatives will serve for one-year terms on MCC's Board of Directors. Mr. Larkin will serve for a special 18-month term to allow for continuity between the two ACRO Board positions with a 6-month overlap between all future representatives.

About ACRO

The Association of Clinical Research Organizations (ACRO) is the professional organization of companies whose focus is clinical research. The association is the voice of the CRO industry, which provides specialized services that are integral to the development of drugs, biologics and medical devices. ACRO helps its members improve the quality, efficiency and safety of biomedical research. For more information on ACRO, please visit http://www.acrohealth.org.

About MCC

The Metrics Champion Consortium (MCC) is an open, multidisciplinary, non-profit organization comprised of biotechnology, pharmaceutical and service provider organizations. The mission of MCC is to develop, through a collaborative process, Performance Metrics within the Biotechnology and Pharmaceutical industry with the intent to jointly encourage performance improvement, effectiveness, efficiency, and appropriate levels of controls for both Sponsors and Service Providers. For more information, please visit http://www.metricschampion.org.


'/>"/>
SOURCE Association of Clinical Research Organizations
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The Cambridge Group Names Philip Marineau a Director
2. The Cambridge Group Names Peter Klein a Director
3. Aethon, Inc. Names New Chief Financial Officer
4. Horizon Therapeutics Names Timothy P. Walbert as President and CEO
5. AARP the Magazine Names the Top 10 Healthiest Places to Live in America
6. Cardica Names Frederick Bauer Vice President of Operations
7. Assurant Health Names Jennifer Kopps-Wagner Senior Vice President and General Counsel
8. MDdatacor Names Gregory Buchholz Chief Operating Officer
9. Zane Benefits Names Halstead New CEO
10. Care Investment Trust Inc. Names Frank E. Plenskofski as Chief Financial Officer and Treasurer
11. University HealthSystem Consortium Names Susan K. Pingleton, MD, as Its Chief Learning Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... IL (PRWEB) , ... October 13, 2017 , ... ... which established the certification process to promote standards of excellence for the field ... Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at the ...
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and ... financial results for the third quarter of 2017 on ... conference call on that day with the investment community ... The conference call will begin at 9 ... can access a live webcast of the conference call ...
(Date:9/28/2017)... -- Cohen Veterans Bioscience and Early Signal Foundation announce ... home sensors for real-time monitoring of patients with trauma-related ... organization focused on disruptive health solutions for rare disorders ... to record and integrate behavioral, cognitive, physiological and contextual ... ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
Breaking Medicine Technology: